Melphalan and bortezomib

PreclinicalSmall molecule

DDartmouth-Hitchcock Medical Center

Melphalan and bortezomib is one of 14 small molecule programs targeting MDS. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MDSCompleted

MDSPreclinical

Completed

Competition

Competitive Landscape

13 competitors in MDS

#DrugCompanyPhaseTrials

Aranesp

Amgen

Phase 3

2 2

Dacogen

Sun Pharmaceutical Industries, Inc.

Phase 2

4 3

Venclexta

AbbVie

Phase 2

2 4

Nplate

Amgen

Phase 2

1 5

Ilaris

Novartis

Phase 2

1 6

Reblozyl

Bristol-Myers Squibb

Phase 2

1 7

Cytoxan

BBaxter Healthcare Corporation

Phase 2

1 8

Talzenna

Pfizer

Phase 1

1 9

Azacitidine or Decitabine

SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2

1 10

Defactinib

VVerastem, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

MDS1 trial

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

Completed·—·N/A·NCT00789256·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Melphalan and bortezomib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Melphalan and bortezomib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Melphalan and bortezomib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dartmouth-Hitchcock Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DDartmouth-Hitchcock Medical Center

Melphalan and bortezomib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

MDS1 trial

References

Drug Info

Quick Facts

Related News